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Abstract
Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with anticancer properties. Here, we
report that (S)-2, a novel hydroxamate-based HDACi, shown previously to be effective against acute myeloid leukemia cells,
was also a potent inducer of apoptosis/differentiation in human prostate LNCaP and PC3 cancer cells. In LNCaP cells (S)-2
was capable of triggering H3/H4 histone acetylation, H2AX phosphorylation as a marker of DNA damage and producing G0/
G1 cell cycle arrest. Consistently, (S)-2 led to enhanced expression of both the protein and mRNA p21 levels in LNCaP cells
but, contrary to SAHA, not in normal non-tumorigenic prostate PNT1A cells. Mechanistic studies demonstrated that (S)-2-
induced apoptosis in LNCaP cells developed through the cleavage of pro-caspase 9 and 3 and of poly(ADP-ribose)-
polymerase accompanied by the dose-dependent loss of mitochondrial membrane potential. Indeed, the addition of the
pan-caspase inhibitor Z-VAD-fmk greatly reduced drug-mediated apoptosis while the antioxidant N-acetyl-cysteine was
virtually ineffective. Importantly, preliminary data with nude mice xenografted with LNCaP cells showed that (S)-2 prompted
a decrease in the tumor volume and an increase in H2AX phosphorylation within the cancer cells. Moreover, the highly
metastatic prostate cancer PC3 cells were also sensitive to (S)-2 that: i) induced growth arrest and moderate apoptosis; ii)
steered cells towards differentiation and neutral lipid accumulation; iii) reduced cell invasiveness potential by decreasing the
amount of MMP-9 activity and up-regulating TIMP-1 expression; and iv) inhibited cell motility and migration through the
Matrigel. Overall, (S)-2 has proven to be a powerful HDACi capable of inducing growth arrest, cell death and/or
differentiation of LNCaP and PC3 prostate cancer cells and, due to its low toxicity and efficacy in vivo, might also be of
clinical interest to support conventional prostate cancer therapy.
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Introduction
Epigenetic changes are reversible chromatin rearrangements
capable of modulating gene expression within the cell without
modifying DNA sequence. Acetylation is the most widely studied
post-translational modification of histone proteins [1] due to the
balanced activity of two families of enzymes, namely the histone
acetyltransferases (HATs) and histone deacetylases (HDACs) that
catalyze the acetylation/deacetylation of histones, respectively,
and thereby modifying chromatin conformation and DNA
accessibility to transcription factors [2,3,4]. Moreover, HATs
and HDACs contribute to modulating gene expression by direct
interaction with nonhistone key regulatory proteins [5] as p53,
GATA1, GATA2, retinoic acid receptor, NF-kB and cytoskeletal
proteins like a-tubulin [6,7,8]. It is not surprising, therefore, that
aberrant activities of these enzymes may repress transcription of
specific onco-suppressor genes and lead, eventually, to tumor
formation [9,10]. And indeed, histone hypoacetylation, due to
over-expression of HDACs, has a recognized role in the
tumorigenesis of different cancers affecting stomach [11], colon
[12,13], breast [14] and prostate [15,16,17].
With particular regard to prostate cancer, this is the most
frequently diagnosed non-cutaneous malignancy and the third
leading cause of cancer-related deaths in men in the Western
world. Although a number of therapeutic options are available for
early prostate cancer, in patients relapsed from primary treatment
with surgery and/or radiation, or presenting metastatic disease,
the androgen deprivation remains the mainstay of therapy.
However, despite the androgen ablation, virtually all tumors
eventually progress with castration-resistant diseases [18,19,20]
which need to be treated with conventional cytotoxics or
epigenetic agents such as HDAC inhibitors (HDACi). The latter
have emerged as a new class of powerful anticancer agents capable
of inducing tumor cell growth arrest, differentiation and/or
apoptosis [16,17] in vitro and acting as radiation sensitizers in
cancer cells by down-regulating DNA repair activity [21,22,23].
Some of these HDACi showed however several limitations in vivo
due to their high toxicity, low solubility, and short half-lives
[24,25]. Therefore, developing novel HDACi with anticancer
properties and low-toxic profiles is a crucial target of translational
research.
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We have previously reported a new set of potent hydroxamate-
based HDACi characterized by a 1,4-benzodiazepine ring (BDZ)
used as the cap and linked, through a triple bond connection unit,
to a linear alkyl chain carrying a hydroxamic function as the Zn++-
chelating group [26]. Among these hybrids, one in particular,
MC133(S)-2 [henceforth (S)-2] showed to be a very effective pro-
apoptotic agent towards different cultured and primary acute
myeloid leukemia (AML) cells in vitro and ex vivo, and was virtually
safe to mice in vivo up to 150 mg/kg/week [27].
In the present study we examined the antitumor potential of (S)-
2 in two of the most widely investigated human epithelial prostate
cancer cell lines, namely the androgen-sensitive LNCaP, and the
androgen-insensitive and highly metastatic PC3, by using the
human nontumorigenic PNT1A prostate epithelial cells as the
control. (S)-2 inhibited prostate cancer cell proliferation, induced
a greater apoptotic response as compared to SAHA (or Vorinostat;
one of the best performing HDACi approved by FDA for
treatment of cutaneous T-cell lymphoma) [28,29] in LNCaP cells
and to a lesser extent also in highly metastatic PC3 cells whose
migration and invasiveness properties were drastically reduced by
the drug. In contrast, normal epithelial prostate PNT1A cells were
virtually drug insensitive. Importantly, (S)-2-induced apoptosis in
LNCaP cells developed through a caspase-dependent mechanism.
Materials and Methods
Cell Culture and Treatments
Nonmetastatic LNCaP and metastatic PC3 prostate cancer
cells, and the human nontumorigenic prostate epithelial PNT1A
cells were a kind gift of P. Chiarugi (Dept. Biochemical Sciences,
University of Florence) who obtained the cell lines from the
European Collection of Cell Cultures [30]. Human prostate cells
were cultured in RPMI 1640 supplemented with 10% fetal bovine
serum (FBS). Cells were maintained at 37Cu in 5% CO2
humidified atmosphere. (S)-2 and SAHA (or Vorinostat; Sigma-
Aldrich, St. Louis, MO, USA) [28,29] were dissolved in dimethyl
sulfoxide (DMSO; Sigma-Aldrich) at 0.1 M concentration and
stored in the dark at room temperature (RT). Working drug
solutions were obtained by appropriate dilution of the stock
solution with the culture medium. DMSO was employed as the
vehicle at a final dose of #0.1% (v/v) in culture for both (S)-2 and
SAHA. In caspase inhibition experiments Z-VAD-fmk (R&D
Systems, Minneapolis, MN, USA) and the anti-oxidant N-Acetyl
Cysteine (NAC; Sigma-Aldrich) were added in culture 2 h prior to
(S)-2 addition.
Cell Cycle Analysis
Prostate cells were treated for 24 h without/with 2.5 mM drug,
then resuspended in a propidium iodide/RNase solution (BD
PharMingen, San Diego, CA) and incubated at RT in the dark for
15–30 min. The percentages of cells relative to G0/G1, G2/M,
and S phase were determined with the aid of Becton Dickinson
FACSCalibur System.
Western blotting
Harvested cells were resuspended in 20 mM RIPA buffer
(pH 7.4) containing a cocktail of proteinase inhibitors (Calbio-
chem, Merck, Darmstadt, Germany) and treated by sonication
(Microson XL-2000, Minisonix, Farmingdale, NY, USA). Proteins
were assayed by the BCA Protein Assay (Thermo Scientific,
Rockford, IL, USA), analysed by SDS-PAGE and western blotting
as reported elsewhere [31]. Membranes were probed with primary
antibodies against: acetyl-H3, acetyl-H4, and H4 (Upstate Bio-
technology, Millipore, Bilerica, MA, USA); PARP, c-H2AX,
H2AX, H3 and Caspase 9 (Cell Signaling Technology, Danvers,
MA, USA); a-tubulin and acetylated a-tubulin (Sigma-Aldrich),
Caspase 3 and p21 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Suitable peroxidase-conjugated IgG preparations (Sigma-
Aldrich) have been used as secondary antibodies; the ECL
procedure was employed for development.
Quantitation of Mitochondrial Membrane Potential
To determine changes in drug-induced transmembrane mito-
chondrial membrane potential (Dym), cells have been stained with
JC-1 (Invitrogen, Life Technologies, Carlsbad, CA, USA),
a cationic dye that exhibits potential-dependent accumulation in
mitochondria, indicated by a fluorescence emission shift from
green (525610 nm) to red (610610 nm). LNCaP cells (0.56106)
were treated without/with 2.5 and 5 mM (S)-2 for 72 h and then
resuspended in RPMI 1640 containing 15 mg/ml of JC-1 dye for
30 min at RT in the dark; after that cells were washed and the
fluorescence was measured by flow cytometry. Mitochondria
depolarization is specifically indicated by a decrease in the red to
green fluorescence intensity ratio [32].
Caspase 3 Activation Assay
Prostate cancer cells (105 cell/ml) were incubated with 2.5 mM
(S)-2 for 48 h and then subjected to the Carboxyfluorescein
FLICA Apoptosis Detection Kit Caspase assay (Caspase 3 FLICA,
Immunochemistry Technology, Bloomington, MN, USA). Cells
were stained with FAM-DEVD-FMK FLICA reagent dissolved in
PBS for 1 h at 37uC, and washed twice in PBS before performing
the cytofluorimetric assay.
Gel Zymography
Analysis of gelatinase (MMP-9) activity was performed as
previously described [33]. Briefly, PC3 cells were seeded in 6-well
plates and treated with increasing amount of (S)-2 in serum-free
media for 24 h. Aliquots of conditioned media (CM) were mixed
with 46 (v/v) sample buffer (0.25 mol/l Tris-HCl, pH 6.8, 0.4%
SDS, 40% glycerol and bromophenol blue), then loaded onto
a 10% SDS gel containing 1 mg/ml gelatin (Sigma-Aldrich) and
run under non-reducing conditions at the constant voltage of 125
V. Following electrophoresis, the gel was incubated in renaturing
buffer (2.5% Triton X-100) at RT for 30 min, washed twice with
distilled water (10 min each time), and then incubated with the
developing buffer (50 mmol/l Tris pH 8.0, 5 mmol/l CaCl2,
0.2 mol/l NaCl and 0.02% Brij-35) at 37Cu overnight, stained in
0.5% Coomassie Blue solution for 2 h and destained with
a solution [5% acetic acid, 10% methanol (v/v) in distilled water]
until bands of gelatinolytic activity were visualized and then
measured by densitometric analysis with Image J Software.
Wound-healing Assay
PC3 cells were cultured in 6-cm plates until confluence and then
the monolayer was scratched using a fine sterile pipette tip to
produce a narrow wound in the substrate. The medium and debris
were aspirated away and replaced with fresh medium in the
presence of different concentrations of (S)-2. Pictures were taken
before and 24 h after wounding with the aid of a Nikon E 4500
photocamera (Nikon) on a Nikon TMS-F phase-contrast micro-
scope (Nikon Instruments, Florence, Italy).
Invasiveness Assay
For these experiments were used Boyden chambers in which the
upper and lower wells were separated by porus polycarbonate
filters coated with matrigel (50 mg/filter) (Becton Dickinson, BD,
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New Jersey, USA). Cultures were pre-treated with/without (S)-2
(2.5–5 mM) for 24 h and then aliquots of PC3 cells (206103) were
transferred in the upper compartment of the chamber. Cell
invasive capability was evaluated after 6 h and expressed as the
absolute number 6 SD of cells present on the filters; five different
microscopic fields for each condition have been examined.
Oil Red O Staining for Neutral Lipids
Neutral lipids were detected (i) histochemically [34] on cell
monolayers which were quickly fixed with 220uC methanol,
stained with Oil Red O (ORO) (Sigma-Aldrich), and (ii)
spectrophotometrically (Cary 50 Scan, Varian, Victoria, Australia)
at 510 nm by recording absorbance of cell-bound ORO following
extraction with isopropanol [35,36]. ORO accumulation was
expressed as relative absorbance unit/mg cell protein.
Quantitative Real Time-PCR Analysis
QRT-PCR was performed with reverse transcripted cDNA of
untreated and treated cells using the Applied Biosystems 7500HT
System according to standard protocols. Fold of p21, MMP-9 and
TIMP-1 induction were calculated by the changes of p21 or
MMP-9 or TIMP-1 Ct values in treated versus untreated cells and
were normalized to the 18S rRNA Ct Amplification was
performed with the default PCR setting: 40 cycles of 95uC for
15 sec and of 60uC for 60 sec using a SYBR Green based
detection (SYBR Green Master mix; Applied Biosystems) and the
following primers: for p21, forward 59-CTGCCCAAGCTC-
TACCTTCC-39 and reverse 59-CAGGTCCA
CATGGTCTTCCT-39; for MMP-9 forward 59-GCTAC-
CACCTCGAA CTTTGAC-39 and reverse 59-TGCCGGATGC-
CATTCAC-39; for TIMP-1, forward 59-CCAACAG
TGTAGGTCTTGGTGAAG-39 and reverse 59-
CTGTGGCTCCCTGGAACA-39; and for 18S rRNA, forward
59CGGCTACCACATCCAAGGAA-39 and reverse 59-
GCTGGAATTACCGCGGCT-39.
Figure 1. (S)-2 induced growth arrest in LNCAP cells. (A) – Cells (105) were seeded in 6-well plates and allowed to attach overnight. On the
next day (S)-2 was added at the indicated concentrations (0–5 mM) and viable cells (trypan blu-negative) were counted with the aid of a Bu¨rker
chamber along the following three days. (B, top) – (S)-2 induced G0/G1 cell cycle arrest and increased p21 expression. LNCaP cells (2610
5) were
treated with 2.5 mM drug for 24 h, then were detached and aliquots of cell suspensions were incubated with a propidium iodide (PI) solution for
30 min and subsequently analyzed by flow cytometry (DNA amount, X-axis; total events, Y-axis). The percentage of cells in the different phases of the
cell cycle was calculated by the ModFit program and shown in each panel. (B, middle) – Phase contrast pictures of companion cultures indicated that
(S)-2 induced morphological changes and a marked decrease in cell density. (B, bottom) – Cells were treated with 2.5 mM drug for the indicated time
points and p21 protein levels were monitored by immunoblotting; GAPDH was also examined to ensure equal loading of samples in each lane. (C) –
LNCaP cell growth arrest was not strictly dependent on the continual presence of drug. Cells have been seeded in 6-well plates (105 cell/well) and
allowed to attach overnight. The day after cultures were added without/with 2.5–5 mM (S)-2 for 3d and then replaced with drug-free medium for
additional 3d and compared to cultures where the drug was steadily maintained up to 6d when viable cells were counted. Each bar represents the
mean obtained from triplicate wells 6 SD.
doi:10.1371/journal.pone.0058267.g001
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Preliminary in vivo Experiments with a Murine Xenograft
Model
The protocol and results regarding this preliminary approach to
in vivo experiment has been reported under the section of
Supporting Information (Figure S1).
Statistical Analysis
The Student’s t-test or one-way analysis of variance were used to
assess statistical significance of results. The difference among the
values was considered significant at P # 0.05.
Results
(S)-2 Prompts LNCaP Cells to G0/G1 Cell Cycle Arrest and
Changes in Morphology
LNCaP cells, cultured without/with increasing (S)-2 concentra-
tions (1, 2.5 and 5 mM) up to 72 h, underwent a dose- and time-
dependent growth arrest to reach 50% of inhibition after two days
of incubation with 1–2.5 mM (S)-2; whereas in cultures treated
with 5 mM the number of viable cells decreased significantly to
levels well below the starting plating density (Figure 1A). The effect
of (S)-2 on LNCaP cell cycle progression as measured by flow
cytometry showed that a 24 h-exposure to 2.5 mM drug increased
significantly the percentage of cells in G0/G1 (from 59 to 93%) and
decreased cell population in S-phase (from 29 to 2%) (Figure 1B,
Figure 2. (S)-2 induced apoptosis in LNCaP cells. (A) – Cells were incubated with the drug (2.5, 5 mM) for the indicated time points. Whole-cell
extracts were analysed by Western immunoblot to detect: phospho-H2AX, that it is triggered following DNA damage; PARP and its cleaved fragment
to denote apoptotic activaction; and acetyl-H4 due to the inhibition of HDAC activity. GAPDH and a-tubulin were used as loading controls. (B) –
Untreated or drug-treated cells (2.5 mM for 48 h) were incubated during the the last 60 min with FAM-DEVD-FMK carboxyfluoresceine, then rinsed
twice with PBS and their green fluorescence was measured by flow cytometry. The frequency histogram of the number of events (Y axis) versus
fluorescein intensity (X axis) showed two peaks: caspase-negative cells (unlabeled cells) were on the left of the P2 region; while caspase-positive cells
which were labeled with Flica occurred within the P2 region. (C) – Treatment with (S)-2 led to a dose-dependent mitochondrial transmembrane
potential (DY) dissipation. This effect was assessed with the aid of JC-1 dye, which aggregates in normal mitochondria and emits red fluorescence
but it can not accumulate in mitochondria which have lost their transmembrane potential, and, therefore emits a diffuse cytoplasmatic green signal
in dead cells. Mitochondrial depolarization is indicated by a decrease in the red/green (R/G) fluorescence intensity ratio [32]. Values have been
normalized by using the control signal (only the vehicle) as an arbitrary value of 100%. Each bar is the mean of two independent experiments
performed in triplicate. (D) – LNCAP cells were treated with (S)-2 (2.5–5 mM) or with (S)-2 (5 mM) plus 15 mM N-Acetyl Cysteine (NAC) applied 2 h
before drug addition. Activation of apoptosis was revealed by the cleavage of PARP and phosphorylation of H2AX and these events as well as the
drug-mediated a-tubulin acetylation were not contrasted by NAC. GAPDH was used as the reference protein. (E) – Z-VAD-fmk prevented the drug-
induced cleavage of PARP and the phosphorylation of H2AX. LNCAP cells were treated as above but, instead of NAC, cultures were preincubated with
30 mM Z-VAD-fmk for 2 h prior to be treated for 24 h with the drug. Cell lysates were analyzed for the cleavage of PARP, the activation of caspase 3
and 9, H2AX phosphorylation as well as acetylation of H4 and a-tubulin; a-tubulin was used as loading control.
doi:10.1371/journal.pone.0058267.g002
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top). In addittion, upon treatment, the typical morphology of
LNCaP cells changed to a spindle-shaped, fairly enlarged
phenotype to yield monolayers that were characterized by a partial
cell loss and reduced contacts among residual cells (Figure 1B,
middle). Consistently, the cell cycle inhibitor p21 protein –
reported to be up-modulated by HDACi [37] – augmented in
a time-dependent manner in response to 2.5 mM (S)-2; the protein
was detected starting from 6 h of treatment, increased after 15 h
and peaked at 24 h (Figure 1B, bottom).
Furthermore, growth arrest of LNCaP exposed to (S)-2 was not
strictly dependent on the continual presence of drug. This
assumption derived from monitoring cell number in cultures
treated without/with 2.5 or 5 mM (S)-2 for 3d and then replaced
with drug-free medium for additional 3d, while in companion
cultures the drug was steadily maintained for 6d. Cells remained
virtually arrested even after the drug-free medium replacement
yielding values which were similar to those of cultures continually
exposed to the drug (Figure 1C).
(S)-2-induced Apoptosis in LNCaP Cells Depends on
Activation of the Caspase Cascade and Disruption of
Mitochondrial Integrity
Among the early HDACi-induced events at DNA level there
were the formation of double strand breaks (DSB) and the
Figure 3. Effects of (S)-2 and SAHA towards LNCAP and PNT1A cells. (A) – LNCAP and PNT1A cells were incubated for 24 h with increasing
amounts of either (S)-2 and SAHA. Cell extracts were subjected to Western immunoblotting to detect phospho-H2AX, PARP and its cleaved fragment
and acetyl-H3; a-tubulin was used as loading control. (B) – p21 mRNA levels from LNCAP and PNT1A cells incubated without/with (S)-2 or SAHA for
24 h were measured by quantitative real-time PCR. Normal PNT1A cells were apparently less sensitive to (S)-2 as compared to SAHA. Columns,
average of three independent samples: bars 6 SD; significant difference (P#0.05). (C) – PARP cleavage and c-H2AX levels induced in LNCaP and
PNT1A cells by a 24 h-treatment without/with (S)-2 were compared on the same blot.
doi:10.1371/journal.pone.0058267.g003
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phosphorylation of H2AX to yield c-H2AX that aids in DNA
damage repair [38]. The response of LNCaP cells to (S)-2 as
determined by immunostaining showed that 2.5 mM drug
significantly increased the c-H2AX signal within 6 h and these
levels were fairly sustained up to 24 h by following a pattern
similar to that of drug-induced acetyl-H4 (Figure 2A, top).
Moreover, the onset of apoptosis, as marked by cleavage of the
caspase substrate poly(ADP-ribose) polymerase (PARP), was
detected from 15 h of treatment and increased steadily up to
48 h (Figure 2A, bottom) when about 80% of LNCAP cells
showed the: (i) drug-mediated activation of caspase 3 (Figure 2B)
and (ii) dose-dependent shift in the JC-1 red/green fluorescence
ratio to denote a progressive dissipation of the mitochondrial
transmembrane potential (DYm) (Figure 2C).
Moreover, to investigate the mechanism of (S)-2-induced
apoptosis in LNCAP cells, the effects of the anti-oxidant N-
acetyl-cysteine (NAC) and of the pan-caspase inhibitor Z-VAD-
fmk were examined separately. Differently from that reported for
AML cells [27], the presence of 15 mM NAC in the culture
medium was not capable of decreasing drug-induced cleavage of
PARP thus ruling out a major role of reactive oxygen species
(ROS) in drug-mediated apoptosis (Figure 2D). Instead, experi-
ments performed without/with 30 mM pan-caspase inhibitor Z-
VAD-fmk revealed that this compound was capable of preventing
drug-mediated activation of caspase 9 and 3 as well as of the
cleavage of PARP and increase in c-H2AX [39], thus suggesting
that (S)-2-induced apoptosis in LNCaP cells developed through
a caspase-dependent mechanism (Figure 2E). It is worth noting
that drug-induced acetylation of H4 and a-tubulin was not
hampered by Z-VAD-fmk.
(S)-2 Targets LNCaP Cells but not Normal Prostate PNT1A
Cells
The potential translational value of (S)-2 was assessed by
comparing the activities of both (S)-2 and SAHA with regard to
induction of apoptosis and histone acetylation on LNCaP cells and
normal prostate epithelial immortalized PNT1A cells. (S)-2
prompted a marked increase in the levels of cleaved PARP
fragment, c-H2AX and acetyl-H3 in LNCaP cells with much
greater efficacy than SAHA (Figure 3A, left). Moreover, (S)-2
seemed to be relatively safe to normal PNT1A cells that, instead,
were a sensitive target of SAHA as revealed by the cleavage of
PARP upon treatment with 5 mM drug (Figure 3A, right) while
acetyl-H3 levels in PNT1A cells remained relatively steady
regardless of either the inducers.
Furthermore, growth arrest in (S)-2-treated LNCAP cells was
associated with a marked dose-dependent increase (7–13 times) in
p21 mRNA levels which were also enhanced by SAHA although
with a less dose-dependent progression (Figure 3B, left). It should
be noted that p21 expression in PNT1A cells was unaffected by
(S)-2, while strikingly up-regulated by 5 mM SAHA (Figure 3B,
Figure 4. PC3 cells undergo growth arrest upon treatment with (S)-2. (A) – Cells (105) were seeded in 6-well plates and allowed to attach
overnight. The day after (S)-2 was added at the indicated concentrations and cell number was determined along the next three days. (B) – Cells were
incubated for 24 h with 2.5 mM (S)-2 to determine the % of PI-stained cells in different phases of the cell cycle as determined by flow cytometry.
Pictures of either untreated and treated cultures were taken with the aid of a phase-contrast microscopy. (C) – p21 mRNA levels in PC3 cells from
cultures treated without/with (S)-2 were measured by quantitative real-time PCR. (D) – Comparative Western blot analysis of acetyl-H3 levels in cell
extracts from PC3 treated with either (S)-2 or SAHA; a-tubulin was used as loading control.
doi:10.1371/journal.pone.0058267.g004
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right). Moreover, results obtained by comparing on the same blot
the effects of (S)-2 in LNCaP and PNT1A cells have clearly proven
that LNCaP were definitely more sensitivity than normal PNT1A
cells in terms of PARP cleavage and c-H2AX levels (Figure 3C).
(S)-2 Induces Cell Cycle Arrest, Apoptosis and
Differentiation of PC3 Cells
The effect of (S)-2 on proliferation of the highly metastatic
prostate cancer PC3 cells has also been evaluated. Cells cultured
for three days without/with increasing amounts of (S)-2 underwent
a dose-dependent inhibition of proliferation (Figure 4A) in keeping
with the significant increase in the proportion of cells arrested in
G0/G1 phase (from 46 to 75%) and the decrease (from 40 to 15%)
Figure 5. PC3 are less sensitive than LNCAP cells to drug-induced apoptosis. (A) – Samples from PC3 and LNCaP cells treated without/with
(S)-2 (2.5 and 5 mM) for 24 h were analysed by Western blot and immunodetected for: PARP and its cleaved fragment, c-H2AX and acetyl-a-tubulin,
while a-tubulin was used as loading control. (B) – Cells either untreated or treated with 2.5 mM (S)-2 for 48 h were incubated just 1 h prior to be
harvested with FAM-DEVD-FMK carboxyfluoresceine and then rinsed twice with PBS and their green fluorescence was measured by flow cytometry
(see comment of point B in Figure 2). (C) – Microscopic evaluation of the effects of (S)-2 on the accumulation of neutral lipid droplets within PC3 cells
treated for three days. After fixation, cells were stained with an ORO solution; quantification of ORO staining was carried out as described in Materials
and Methods.
doi:10.1371/journal.pone.0058267.g005
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of cells in S phase (Figure 4B). Consistently, p21 was significantly
up-regulated at 15 and 24 h of treatment (Figure 4C). Of interest,
(S)-2-induced acetyl-H3 levels were already enhanced at 24 h and
rose further at 48 h, just when the effect of SAHA began to decline
(Figure 4D).
However, PC3 cells, despite their sensitivity to (S)-2-mediated
cytostasis, seemed to be more resistant than LNCaP cells to drug-
induced apoptosis as shown by the fact that a similar pattern of
cleaved PARP, c-H2AX and acetyl-a-tubulin in the two cell lines
could be obtained only by treating PC3 cells with twice the dosage
employed for LNCaP cells (Figure 5A). Furthermore, the
Figure 6. (S)-2 reduces invasiveness, migration and motility potential of PC3 cells. (A) – Aliquots of conditioned media from PC3 cultures
incubated without/with (S)-2 in the absence of FCS were submitted to gelatin zymography and densitometric analysis of MMP-9 activity (percentage
of control). (B) – MMP-9 and TIMP-1 mRNA levels from PC3 cells treated without/with (S)-2 for 24 h were determined by quantitative real-time PCR.
(C) – (S)-2 inhibited PC3 cell motility in vitro. Confluent cultures were ‘‘wounded’’ with the aid of a sterile plastic tip and maintained without/with
increasing amounts of drug for 24 h. A phase-contrast microscopy was used to take pictures of the monolayers. (D) – (S)-2 decreased invasiveness of
PC3. Cultures were pre-treated with/without (S)-2 (2.5–5 mM) for 24 h and then aliquots of PC3 cells (206103) were transferred in the upper
compartment of the chamber. Cells migrated through the Matrigel on the filters of Boyden chambers were counted after 6 h and expressed as the
absolute cell number6 SD; five different microscopic fields (magnification: x200) for each condition were examined and significant difference among
specimens was established at P#0.05.
doi:10.1371/journal.pone.0058267.g006
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fluorescent assay for caspase 3 activation by 2.5 mM (S)-2
indicated that about 23% of PC3 cells underwent apoptosis after
a 48 h-treatment (Figure 5B) i.e. less than one-third relative to
treated LNCAP cells. In addition, PC3 cells remaining on the dish
following incubation for 72 h with increasing amounts of drug
became larger in size relative to controls and accumulated within
the cytoplasm neutral lipid droplets, staining positively with Oil-
Red O (ORO) as the result of drug-induced adipogenic
differentiation (Figure 5C) that was already reported to occur in
these cells [40].
(S)-2 Reduces Invasiveness, Migration and Motility of PC3
Cells
Matrix metalloproteinases (MMPs) released by tumor cells into
the extracellular environment are crucial for cancer-promoted
tissue degradation and invasion along with the metastatic process
[41,42,43]. MMP-9 from the conditioned medium of PC3 cultures
was submitted to gelatin zymography and showed a dose-de-
pendent decrease of MMP-9 activity (Figure 6A) that was
accompanied by a slight, yet not significant, decline in MMP-9
expression (Figure 6B, left). Instead, the expression of the tissue
inhibitor of metalloproteinase-1 (TIMP-1) – known to exert anti-
metastatic effects by contrasting the activity of MMP-9 and other
MMPs [44,45] – was strikingly enhanced after 24 h of treatment
(Figure 6B, right).
Moreover, results of the ‘‘wound healing’’ assay in vitro showed
that in untreated cultures the wounded area was completely
refilled within 24 h, while in drug-treated cultures cell migration
and motility was decreased in a dose-dependent manner
(Figure 6C). Finally, the invasive potential of PC3 cells through
the Matrigel was markedly inhibited after 24 h of incubation with
increasing (S)-2 concentrations as shown by the number of stained
cells on the filters of Boyden chambers and related pictures
(Figure 6D).
Discussion
Anticancer properties of the novel HDACi (S)-2 on LNCaP and
PC3 prostate carcinoma cells have been evaluated in this work by
using the PNT1A cells as the normal prostate epithelial
counterpart and SAHA as the prototype of hydroxamate-based
HDACis. (S)-2 exerted a broad spectrum of effects towards
prostate cancer cells including G0/G1 cell cycle arrest, p21 up-
regulation, histone hyperacetylation and induction of apoptosis as
showed by the caspase cascade activation, the cleavage of PARP,
the disruption of mitochondrial integrity and DNA damage. These
events, as thouroughly explained in the previuos section, were
prompted by low micromolar drug dosages and within a relatively
short time (6–72 h). Thus, rather than reiterate specific experi-
mental details, it is useful to address a few, but important points.
First, (S)-2 proves to be a more effective agent than SAHA as
concerns the extent and duration of drug-induced PARP cleavage
activity in both LNCaP and PC3 cells as well as its safety towards
normal epithelial prostate PNT1A cells. Moreover, SAHA was
reported to recognize the androgen-dependent prostate LNCaP
and CWR22 cells as sensitive targets, but not the androgen-
independent PC-3 and TSU-Pr1 cells which showed a modest
drug-induced growth arrest with a little detectable cell death [46].
Second, mechanistic studies indicated that (S)-2-induced apo-
ptosis in LNCaP cells was mainly based on caspase cascade
activation. Conversely, pro-apoptotic effects of (S)-2 in different
AML cell types, developed through a ROS-dependent mechanism
[27]. This might suggest that (S)-2 is able to effectively trigger
apoptosis in both hematological (AML) and solid prostate
carcinoma (LNCaP) cells although via two distinct pathways. On
the other hand, SAHA-induced apoptosis in LNCaP, but not in
PC3 cells [46], was ascribed to drug-induced ROS accumulation
and, consistently, was significantly contrasted by thioredoxin [47].
Third, nonmetastatic LNCaP cells were apparently more
sensitive than metastatic PC3 cells to (S)-2-induced apoptosis.
However, this does not mean that the drug was poorly effective on
PC3 cells, but, more properly, that PC3 response to (S)-2 is the
combined result of multiple different processes that, in addition to
partial growth arrest and apoptosis, also include: (i) changes in cell
morphology and neutral lipid accumulation in residual cells as
a part of drug-induced differentiation [40], and (ii) most
importantly, a striking drug-induced inhibition in cell invasion,
motility and migration through the Matrigel, which are crucial
steps in tumor progression and dissemination of metastatic cells,
and consistent with the increase in acetylated a-tubulin that it is
present in stable microtubules but is absent from dynamic cellular
structures [48]. Overall, these events are, prospectively, more
significant for contrasting highly metastatic and drug-resistant cells
like p53-null PC3 rather than for nonmetastatic cells such as
LNCaP for which a clnical treatment might be easier and with
a more favourable outcome.Furthermore, both (S)-2 and SAHA
share the same hydroxamic function as a zinc-chelating group but
differ in the cap portion: SAHA has a small achiral hydrophilic
anilido group whereas in (S)-2 there is a bulky lipophilic 5-phenyl-
1,4-benzodiazepin-3-one ring carrying a stereogenic center
important for activity [26,27]. Also, in (S)-2, linker and cap are
joined through a metabolically stable triple bond that is typical of
oxamflatin [49], while in SAHA these two domains are connected
through an hydrolysable amide bond. Looking at these chemical
differences, it is not surprising that (S)-2 and SAHA display distinct
biological efficacy and action mechanisms in prostate and other
cancer cells.
And finally, preliminary experiments with nude mice xeno-
grafted with LNCaP cells showed that (S)-2 was capable of
reducing the tumor volume and increasing c-H2AX levels within
tumor cells in vivo as the best evidence for drug-induced caspase
activation and DNA damage (Figure S1).
On the whole, (S)-2 showed to be a safe HDACi in vivo [27] with
powerful anti-proliferative, pro-apototic and differentiative prop-
erties towards nonmetastatic and higly metatastatic prostate
carcinoma cells, making this agent of potential clinical interest in
support of conventional therapy for this and, possibly, other types
of cancer.
Supporting Information
Figure S1 Preliminary in vivo experiments with a mu-
rine xenograft model. Male nude (nu/nu) athymic mice
(Harlan Laboratories, Srl, San Pietro al Natisone, UD, Italy) were
cared for and maintained in accordance with applicable European
Animal Welfare regulations under an approved Institutional
Animal Care and Use Protocol in an animal facility at University
of Florence accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care. Aliquots of LNCaP cell
suspension (36106 cell/100 ml containing an equal volume of
RPMI and matrigel) were implanted subcutaneously on the left
flank of 12 mice [50]. A week later the tumor mass was present
only in eight out of the originally injected mice (66% of tumor
incidence) which were then randomized into two equal groups and
drug treatment was started. (S)-2 was formulated as a DMSO
solution and injected intraperitoneally. One group was treated
with the drug (50 ml final volume, at 65 mg/kg, corresponding to
approximately 2 mg/mouse) three times a week for two weeks,
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while the control group was treated with 50 ml DMSO alone as the
vehicle. Mice were killed after 6 treatments and 24 h post-dose by
cervical dislocation. (A) – Tumors were measured by calipers after
the sacrifice (bottom); the tumor mass was weighed and the
volume was calculated according to the formula length6width26
p/6 (top). In all cases, tumor volumes in untreated mice were
significantly larger relative to those of drug-treated mice to suggest
that (S)-2 was capable of reaching the cancer cells and decreasing
their growth rates. Photographs are representative of a tumor mass
from a mouse treated with either the vehicle or (S)-2, respectively.
(B) – For immunohistochemistry, slides with 2.5–5 mm sections of
paraffin embedded tumor mass were first deparaffinized, boiled in
1 mM EDTA pH 9 for 15 min and after cooling aspecific
peroxidases were blocked with 3% H2O2 for 10 min. Then, slides
were according to standard procedures and incubated with
a primary antibody against c-H2AX (see Materials and Methods)
followed by a peroxidase-conjugated IgG preparation; 3,39-
diaminobenzidine was used as the chromogen for development.
Slides were counterstained with aqueous Meyer hematoxylin and
mounted with glycerol for visual inspection and photography;
pictures are representative of four randomly chosen microscopic
fields (magnification: x400). c-H2AX-positive cells were frequently
observed within the tumor mass of drug-treated mice but not of
mice injected with the vehicle only as depicted by the pictures
(bottom) and clearly indicated by the histograms (top). Statistical
analysis was carried out by Student’s t-test and significant
differences between the two groups were indicated by the asterisks
(*P,0.05; ***P,0.001). Importantly, as reported elsewhere in
CD-1 mice [27], no specific drug-induced histologic alteration in
May-Gru¨nwald Giemsa-stained liver parenchymal cells was
observed (data not shown).
(EPS)
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